All Releases
Sep 21, 2015
AUSTIN, Texas, Sept. 21, 2015 (GLOBE NEWSWIRE) -- Pain Therapeutics, Inc. (Nasdaq:PTIE) today reported that the National Institutes of Health (NIH) has awarded the Company a $1.7 million innovation grant. This grant award provides a path forward for the Company to develop a small molecule drug,
Jul 23, 2015

Company is Focused on REMOXY NDA Resubmission, Targeted for Q1 2016

May 12, 2015
REMOXY Meets Both Primary Endpoints with Statistical Significance ( p < 0.0001) AUSTIN, Texas, May 12, 2015 (GLOBE NEWSWIRE) -- Pain Therapeutics, Inc., (Nasdaq:PTIE) today announced top-line results of an FDA Category 3 Human Abuse Potential Study with REMOXY Extended-Release Capsules CII, its
May 11, 2015

Conference Call Tomorrow, Tuesday, at 4:30 p.m. Eastern Time

May 07, 2015
- REMOXY ® Transition Nears Completion, Setting Stage for Eventual NDA Resubmission - AUSTIN, Texas, May 7, 2015 (GLOBE NEWSWIRE) -- Pain Therapeutics, Inc. (Nasdaq:PTIE) today reported financial results for the quarter ended March 31, 2015. Net loss in Q1 2015 was $2.6 million, or $0.06 per
Apr 23, 2015
AUSTIN, Texas, April 23, 2015 (GLOBE NEWSWIRE) -- Pain Therapeutics, Inc. (Nasdaq:PTIE), a clinical-stage biopharmaceutical company, announced the appointment of Michael Marsman, Pharm.D., as Senior Vice President, Regulatory Affairs. Dr. Marsman will be responsible for developing and implementing
Apr 21, 2015
AUSTIN, Texas, April 21, 2015 (GLOBE NEWSWIRE) -- Pain Therapeutics, Inc. (Nasdaq:PTIE) today reported it had recently resumed responsibility for REMOXY ® under the terms of a letter agreement with Pfizer. The letter agreement was entered into within the scope of the previously disclosed